CA3205212A1 - Pharmaceutical compositions for treating breast cancers and methods of uses thereof - Google Patents

Pharmaceutical compositions for treating breast cancers and methods of uses thereof

Info

Publication number
CA3205212A1
CA3205212A1 CA3205212A CA3205212A CA3205212A1 CA 3205212 A1 CA3205212 A1 CA 3205212A1 CA 3205212 A CA3205212 A CA 3205212A CA 3205212 A CA3205212 A CA 3205212A CA 3205212 A1 CA3205212 A1 CA 3205212A1
Authority
CA
Canada
Prior art keywords
breast cancer
positive
treating
subject
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3205212A
Other languages
English (en)
French (fr)
Inventor
Mitchell Steiner
Ramesh Narayanan
Sunjoo Ahn
James Dalton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/151,108 external-priority patent/US12685719B2/en
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of CA3205212A1 publication Critical patent/CA3205212A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3205212A 2021-01-15 2022-01-14 Pharmaceutical compositions for treating breast cancers and methods of uses thereof Pending CA3205212A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/151,108 2021-01-15
US17/151,108 US12685719B2 (en) 2012-07-13 2021-01-15 Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4/6 inhibitors
PCT/US2022/012631 WO2022155543A1 (en) 2021-01-15 2022-01-14 Pharmaceutical compositions for treating breast cancers and methods of uses thereof

Publications (1)

Publication Number Publication Date
CA3205212A1 true CA3205212A1 (en) 2022-07-21

Family

ID=82448697

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3205212A Pending CA3205212A1 (en) 2021-01-15 2022-01-14 Pharmaceutical compositions for treating breast cancers and methods of uses thereof

Country Status (10)

Country Link
EP (1) EP4277613A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024503718A (cg-RX-API-DMAC7.html)
KR (1) KR20230163362A (cg-RX-API-DMAC7.html)
CN (1) CN116981451A (cg-RX-API-DMAC7.html)
AU (1) AU2022208712A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023014247A2 (cg-RX-API-DMAC7.html)
CA (1) CA3205212A1 (cg-RX-API-DMAC7.html)
IL (1) IL304467A (cg-RX-API-DMAC7.html)
MX (1) MX2023008375A (cg-RX-API-DMAC7.html)
WO (1) WO2022155543A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12685719B2 (en) 2012-07-13 2026-07-21 University Of Tennessee Research Foundation Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4/6 inhibitors
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN117982655B (zh) * 2023-11-21 2024-10-15 北京大学人民医院 芳香化酶抑制剂治疗相关的疼痛动物模型构建方法及应用
WO2025208260A1 (zh) * 2024-04-01 2025-10-09 北京脑科学与类脑研究所 丙酰胺类雄激素受体拮抗剂及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070066568A1 (en) * 2005-08-31 2007-03-22 Dalton James T Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
HRP20040818A2 (en) * 2002-02-28 2005-02-28 University Of Tennessee Research Foundation Haloacetamide and azide substituted compounds and methods of use thereof
US10314807B2 (en) * 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10258596B2 (en) * 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
EP3733170A1 (en) * 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
US10987334B2 (en) * 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
KR101709601B1 (ko) * 2016-05-30 2017-02-23 주식회사 에스앤지바이오텍 고정부가 형성된 가이드부재를 포함하는 스텐트 삽입장치
WO2017223115A1 (en) * 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
WO2020028593A1 (en) * 2018-07-31 2020-02-06 Oncternal Therapeutics, Inc. A method of treating er mutant expressing breast cancers with selective androgen receptor modulators (sarms)
WO2020206035A1 (en) * 2019-04-01 2020-10-08 G1 Therapeutics, Inc. Treatment of cdk4/6 inhibitor resistant neoplastic disorders

Also Published As

Publication number Publication date
BR112023014247A2 (pt) 2023-10-03
KR20230163362A (ko) 2023-11-30
WO2022155543A1 (en) 2022-07-21
JP2024503718A (ja) 2024-01-26
IL304467A (en) 2023-09-01
EP4277613A4 (en) 2024-11-20
EP4277613A1 (en) 2023-11-22
AU2022208712A9 (en) 2024-09-19
MX2023008375A (es) 2023-10-05
AU2022208712A1 (en) 2023-08-10
CN116981451A (zh) 2023-10-31

Similar Documents

Publication Publication Date Title
US12115146B2 (en) Treatment of skeletal-related events for breast cancer patients
JP6386120B2 (ja) 選択的アンドロゲン受容体モジュレーター(sarm)によりアンドロゲン受容体(ar)陽性乳癌を処置する方法
US9969683B2 (en) Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
AU2013203600B9 (en) A method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9622992B2 (en) Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
EP4277613A1 (en) Pharmaceutical compositions for treating breast cancers and methods of uses thereof
US10314807B2 (en) Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
WO2020028593A9 (en) A method of treating er mutant expressing breast cancers with selective androgen receptor modulators (sarms)
US20220257552A1 (en) Methods of prescreening and treating breast cancers with selective androgen receptor modulators
US20210228529A1 (en) Pharmaceutical compositions for treating breast cancers and methods of uses thereof
US20230172897A1 (en) Methods of treating breast cancers with selective androgen receptor modulators and additional therapeutic agents

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250110

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250110

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260225

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260526